Temperature-controlled pharmaceutical shipments, especially small parcels, are witnessing significant growth, constituting about 4% of global air cargo tonnage. The small parcel segment is projected to experience double-digit expansion in the near future, presenting a notable challenge for contract pharma companies. Delphine Perridy, Envirotainer’s Chief Commercial Officer, delves into why small parcels are becoming a crucial test for contract pharma in the evolving pharmaceutical landscape.
In today’s complex pharmaceutical environment, characterized by decentralized clinical trials and personalized medicines, small parcel shipments are playing an increasingly vital role. Contract development and manufacturing organizations (CDMOs) rely on small parcels to bridge the gap between innovative therapies and patients in need. However, managing these small parcels poses unique risks and opportunities, especially when catering to multiple clients simultaneously. Each shipment must adhere to stringent temperature control and regulatory standards while ensuring transparency and risk mitigation throughout the shipping process.
The escalating demand for small parcel shipments, particularly in clinical trials and advanced therapies, is transforming pharmaceutical logistics. These shipments necessitate swift movement through various checkpoints and last-mile delivery networks, leaving no room for errors. As treatments become more time-sensitive and personalized, any delays or deviations in temperature control could jeopardize treatment effectiveness, leading to costly consequences. Precision, speed, and security are paramount for every small parcel shipment.
To safeguard high-value pharmaceutical shipments, the industry is turning to advanced packaging technologies such as Phase Change Materials (PCMs) and Vacuum Insulated Panels (VIPs). These innovations help maintain consistent internal conditions, protect products from external influences, and ensure compliance with global GDP regulations. Sustainable packaging solutions not only enhance temperature control but also support CDMOs in meeting environmental goals, regulatory mandates, and client expectations while maintaining operational efficiency.
CDMOs must strike a delicate balance between efficiency, flexibility, and sustainability in their packaging decisions. The industry is increasingly emphasizing sustainability, aiming to achieve a green supply chain by 2030. Selecting reusable packaging solutions that minimize waste and carbon emissions is crucial, aligning with environmental targets and cost-effectiveness. While forever-use packaging is ideal for reducing waste and emissions, single-use options remain essential for complex or remote routes where return logistics are challenging.
As the demand for small parcel shipments rises, close collaboration across the supply chain is vital. CDMOs can gain a competitive edge by scaling compliant packaging swiftly, but this requires strategic partnerships with cold chain experts and pharmaceutical companies. Lasting collaborations drive innovation, reduce costs, and enhance operational efficiency, ultimately leading to better patient outcomes. Embracing smarter packaging, sustainability practices, and collaborative frameworks is key to future-proofing logistics strategies in the pharmaceutical supply chain.
Key Takeaways:
– Small parcel shipments are gaining prominence in pharmaceutical logistics, demanding precise temperature control and strict regulatory compliance.
– Innovative packaging technologies like PCMs and VIPs play a crucial role in maintaining product integrity during transit.
– Sustainability is becoming a non-negotiable aspect of packaging decisions, with the industry moving towards green supply chains by 2030.
– Strategic partnerships across the supply chain are essential for CDMOs to meet evolving regulatory and patient needs while ensuring efficient and safe delivery of pharmaceutical shipments.
Tags: regulatory
Read more on cargoforwarder.eu